Does Mounjaro Cause Fatigue? FDA Label, SURPASS-1 Data & T2D Hypoglycemia Evidence

Mounjaro (tirzepatide) is approved by the FDA for type 2 diabetes — the same molecule as Zepbound, but a different label, different pivotal trials, and different at-risk patient population. Patients searching “Mounjaro fatigue” almost always have type 2 diabetes and are usually on at least one other glucose-lowering agent (most often metformin, often basal insulin, sometimes a sulfonylurea). The fatigue conversation on Mounjaro is therefore not just about the GLP-1/GIP receptor effects — it is about how glucose control interacts with the rest of the diabetes regimen. This article walks through what the SURPASS-1 monotherapy trial and the pooled SURPASS-1 + SURPASS-5 placebo-controlled safety pool actually reported, what the Section 5.3 hypoglycemia warning means in practice, why fatigue appears on the Zepbound label but not on the Mounjaro label (despite being the same molecule), and the specific T2D-flavored management protocol that resolves most cases.

At a glance

• Fatigue is not in Mounjaro Table 1. The Section 6.1 ≥5% list is nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia, abdominal pain^[4]. Fatigue and asthenia are absent — unlike Zepbound, where SURMOUNT-1 reported fatigue at 5–7% vs 3% placebo^[3].
• The dominant T2D fatigue driver is hypoglycemia from combination therapy. Section 5.3^[4] warns that concomitant insulin or insulin secretagogues (sulfonylureas) increase hypoglycemia risk. Table 2 reports blood glucose under 54 mg/dL in 13% on placebo, 16% on Mounjaro 5 mg, 19% on 10 mg, and 14% on 15 mg when added to basal insulin.
• SURPASS-1 monotherapy hypoglycemia was zero. The 40-week monotherapy trial in T2D reported severe hypoglycemia 0/0/0/0% across placebo/5/10/15 mg^[1]. Mounjaro alone (without insulin or a sulfonylurea) is not a meaningful hypoglycemia risk in T2D.
• GI-induced dehydration drives a second tier of fatigue. GI adverse reactions occurred in 37–44% of Mounjaro-treated patients^[4]; Section 5.5 warns about postmarketing acute kidney injury cases following dehydration from GI side effects.
• Caloric deficit explains most non-hypoglycemic titration fatigue. Same mechanism that drives Zepbound titration fatigue; resolves within 2–4 weeks at a stable dose.
• Persistent fatigue at a stable dose warrants labs. Differential diagnosis includes iron, B12, vitamin D, TSH, and HbA1c — not Mounjaro monitoring requirements, but standard primary-care fatigue workup.

What the Mounjaro FDA label actually says about fatigue

Section 6.1 of the Mounjaro prescribing information^[4] — the Clinical Trials Experience section that lists adverse reactions verbatim — defines “common adverse reactions” as those that occurred in at least 5% of MOUNJARO-treated patients and more commonly than on placebo. The full Table 1 from the placebo-controlled pool (SURPASS-1 monotherapy plus SURPASS-5 basal-insulin combination):

Fatigue, asthenia, lethargy, and malaise are absent from Mounjaro Table 1. This is a meaningful contrast with the Zepbound label, where Section 6.1 explicitly lists fatigue at 5% (5 mg), 6% (10 mg), and 7% (15 mg) versus 3% on placebo with a footnote that the entry includes asthenia, fatigue, lethargy, and malaise^[5]. Same molecule, two different labels, two different adverse-reaction tables.

The most plausible explanation is the underlying trial population and observation duration. Zepbound’s label cites SURMOUNT-1^[3], a 72-week obesity trial that drove 20.9% body-weight loss at 15 mg — a magnitude that creates a sustained caloric deficit large enough to produce a fatigue signal above background. Mounjaro’s label cites the 40-week placebo-controlled T2D pool (SURPASS-1 monotherapy and SURPASS-5 basal-insulin combination), where the weight-loss magnitude was substantially smaller — SURPASS-1 reported about 7–9 kg weight loss over 40 weeks^[1], roughly a third of the SURMOUNT-1 magnitude. The caloric deficit signal that drove the SURMOUNT-1 fatigue rate is smaller in the T2D-population trials underlying the Mounjaro label, plausibly below the ≥5% threshold required for Table 1 inclusion.

That does not mean Mounjaro patients do not experience fatigue. It means fatigue did not cross the labeling threshold for Mounjaro’s specific T2D pivotal pool. The mechanism is still present; the magnitude is just below the cutoff for the adverse-reaction table.

SURPASS-1: the Mounjaro monotherapy trial

SURPASS-1^[1] was the Phase 3 pivotal monotherapy trial supporting the Mounjaro T2D approval. It randomized 478 adults with T2D inadequately controlled on diet and exercise alone (mean HbA1c 7.9%, mean diabetes duration 4.7 years) to weekly tirzepatide 5 mg, 10 mg, 15 mg, or placebo for 40 weeks. The trial reported HbA1c reductions of 1.87%, 1.89%, and 2.07% on the three Mounjaro doses versus 0.04% on placebo, and weight reductions of 7.0, 7.8, and 9.5 kg respectively.

Critically for the fatigue question, SURPASS-1 reported zero episodes of severe hypoglycemia and zero episodes of clinically significant hypoglycemia (blood glucose below 54 mg/dL) in any Mounjaro arm or the placebo arm across 40 weeks of monotherapy^[4]. The implication for fatigue is direct: in T2D monotherapy without insulin or a sulfonylurea on board, hypoglycemic fatigue from Mounjaro is not a meaningful clinical concern. The mechanism that does drive fatigue in this monotherapy setting is the same one that drives Zepbound titration fatigue — caloric deficit and GI-related dehydration — but at a lower magnitude than SURMOUNT-1 because the weight-loss target is smaller.

The T2D-specific fatigue driver: hypoglycemia in combination therapy

Section 5.3 of the Mounjaro label^[4] is the load-bearing warning for fatigue in real-world T2D practice. Verbatim:

Patients receiving MOUNJARO in combination with an insulin secretagogue (e.g., sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia. The risk of hypoglycemia may be lowered by a reduction in the dose of sulfonylurea (or other concomitantly administered insulin secretagogue) or insulin.^[4]

Hypoglycemia is one of the classical causes of acute fatigue, and recurrent hypoglycemia (especially mild or below-symptomatic-threshold) is associated with chronic fatigue and impaired daytime function in T2D. Table 2 of the Mounjaro label quantifies the risk by background regimen:

The pattern is clear: hypoglycemia incidence on Mounjaro is almost entirely driven by what else the patient is on. On monotherapy, severe hypoglycemia is zero. Add basal insulin and clinically significant hypoglycemia jumps to 14–19%; severe hypoglycemia appears at 1–2%. Add a sulfonylurea and clinically significant hypoglycemia runs 10–14%.

For patients on combination therapy, the practical implication is that any new fatigue episode warrants a glucose check before attributing it to “just the Mounjaro”. The classical hypoglycemia symptom cluster — fatigue plus sweating, tremor, palpitations, hunger, anxiety, confusion, or vision changes — should trigger a capillary blood glucose reading immediately, with 15 g of rapid-acting carbohydrate (juice, glucose tablets) if the reading is below 70 mg/dL. Persistent overnight tiredness on waking can be a sign of nocturnal hypoglycemia and is worth flagging to a prescriber, who can order a continuous glucose monitor (CGM) trial for diagnostic clarity.

The Mounjaro label’s explicit recommendation is dose reduction of the concomitant insulin or sulfonylurea when starting Mounjaro, not dose reduction of Mounjaro. The default clinical pattern is to reduce basal insulin by roughly 20% and to consider stopping the sulfonylurea or moving to a lower-risk agent before starting Mounjaro in patients with already-good glycemic control. Patients who notice new fatigue should ask their prescriber to revisit the rest of the diabetes regimen rather than just titrate down on Mounjaro.

Dehydration from GI losses — the second-tier driver

Section 5.5 of the Mounjaro label^[4] describes the postmarketing acute kidney injury cases that have been reported with MOUNJARO and the GLP-1 receptor agonist class. The majority occurred in patients who experienced GI adverse reactions leading to dehydration. Verbatim:

There have been postmarketing reports of acute kidney injury, in some cases requiring hemodialysis, in patients treated with GLP-1 receptor agonists, or MOUNJARO. The majority of the reported events occurred in patients who experienced gastrointestinal adverse reactions leading to dehydration such as nausea, vomiting, or diarrhea. Monitor renal function in patients reporting adverse reactions to MOUNJARO that could lead to volume depletion, especially during dosage initiation and escalation of MOUNJARO.^[4]

Dehydration alone (without progressing to acute kidney injury) is a well-established cause of fatigue. Even a 1–2% body-water deficit is enough to reduce energy, cognitive performance, and physical capacity. In Mounjaro pivotal trials, GI adverse reactions occurred in 37.1% (5 mg), 39.6% (10 mg), and 43.6% (15 mg) of patients versus 20.4% on placebo^[4], and 3.0%, 5.4%, and 6.6% of Mounjaro-treated patients respectively discontinued because of GI symptoms. The majority of nausea, vomiting, and diarrhea reports occurred during dose escalation and decreased over time — the same titration-phase pattern as Zepbound.

Layered onto this, tirzepatide acts on central GLP-1 and GIP receptor populations that overlap with hypothalamic circuits regulating both hunger and thirst. Patients on Mounjaro commonly describe reduced spontaneous thirst alongside reduced spontaneous hunger. The combination of GI fluid losses, reduced fluid intake, and blunted thirst drive produces a mild chronic underhydration that maps directly onto the titration-phase fatigue pattern. Active hydration (tracked, not thirst-driven) is the first-line management response.

Caloric deficit — the same mechanism as Zepbound, smaller magnitude

SURPASS-1^[1] participants on 15 mg lost 9.5 kg over 40 weeks — meaningful but smaller than the 20.9% body-weight loss in SURMOUNT-1 obesity participants on the same 15 mg dose^[3]. The mechanism is identical: tirzepatide suppresses appetite, total caloric intake drops, the body runs on fewer calories than habitually consumed, and during the weeks immediately after each dose escalation the metabolic rate has not yet adapted. The result is a temporary energy gap that maps onto the same low-grade titration fatigue seen on Zepbound — just at a smaller magnitude in the T2D population because the weight-loss target is smaller.

SURPASS-2^[2] reinforces the same pattern in a head-to-head T2D trial. Tirzepatide 5/10/15 mg added to metformin reduced HbA1c by 2.01%, 2.24%, and 2.30% versus 1.86% for semaglutide 1 mg, with weight reductions of 7.6, 9.3, and 11.2 kg versus 5.7 kg. The AE profiles in both arms were GI-dominant; neither label nor primary publication identifies fatigue as a top-tier signal at the 5% threshold. The implication: in T2D, the GI cluster is the load-bearing adverse-reaction story; fatigue is a downstream consequence of GI symptoms, caloric deficit, and hypoglycemia rather than a direct drug-receptor effect.

Timeline — when Mounjaro fatigue starts and resolves

Mounjaro uses the same monthly titration ladder as Zepbound: 2.5 mg (weeks 1–4) → 5 mg (weeks 5–8) → 7.5 mg (weeks 9–12) → 10 mg (weeks 13–16) → 12.5 mg (weeks 17–20) → 15 mg (weeks 21+). The 2.5 mg starting dose is sub-therapeutic for glycemic control and exists for tolerability. Fatigue, when it appears, tracks the same titration-phase pattern as Zepbound:

• Weeks 1–4 (2.5 mg starter): mild fatigue if any; mild GI symptoms in a minority. Hypoglycemia uncommon even on combination therapy because the dose is sub-therapeutic.
• Weeks 5–8 (5 mg, first therapeutic dose): GI symptoms peak. If the patient is on background insulin or sulfonylurea, this is the dose at which hypoglycemic episodes typically begin if the concomitant agent has not already been dose-reduced.
• Weeks 9–16 (7.5–10 mg): further GI escalation; caloric deficit deepens; weight loss accelerates. Hypoglycemia risk on combination therapy is highest in this window because background insulin or sulfonylurea was titrated for the pre-Mounjaro glycemic state.
• Weeks 17+ (12.5–15 mg): by maintenance dose, GI symptoms have typically attenuated, HbA1c has dropped substantially, and the diabetes regimen has usually been adjusted by the prescriber. Persistent fatigue at this stage warrants a labs workup.

The pattern can reset with each escalation step — feeling fine at 5 mg, then tired again for 1–2 weeks after moving to 7.5 mg. This is the expected titration pattern, not a sign that Mounjaro “is not working” or that fatigue will be permanent. Standard clinical responses are to extend the current dose period by 4 weeks before escalating, optimize hydration and protein intake, and (for patients on combination therapy) re-check whether the concomitant insulin or sulfonylurea dose can be reduced further.

How Mounjaro fatigue differs from Zepbound fatigue

Same molecule, different population, different label. The Zepbound label^[5] lists fatigue at 5–7% across doses (SURMOUNT-1 obesity population, 72 weeks); the Mounjaro label^[4] does not list fatigue in the Section 6.1 ≥5% Table 1 (SURPASS-1 + SURPASS-5 T2D pool, 40 weeks). Three things explain the difference:

1. Weight-loss magnitude. SURMOUNT-1 drove 20.9% body-weight loss at 15 mg; SURPASS-1 drove about 9.5 kg (roughly 10%). The caloric deficit signal that drives fatigue is smaller in T2D pivotal trials.
2. Trial duration. SURMOUNT-1 ran 72 weeks; the Mounjaro pool ran 40 weeks. The longer trial captures micronutrient-gap fatigue that emerges only with sustained caloric restriction over 6+ months.
3. The hypoglycemia axis is the dominant T2D fatigue driver, not a direct drug AE. Hypoglycemia from combination therapy is captured in Section 5.3 and Table 2, not Table 1. Patients on combination therapy can experience significant fatigue burden from hypoglycemic episodes even when the direct drug-attributable fatigue rate is below the labeling threshold.

Patients who switched to Mounjaro from Zepbound (or vice versa) sometimes report a perceived difference in fatigue burden. The most plausible explanation is the diabetes regimen, not the molecule. A Zepbound patient with no background insulin will have a different fatigue pattern from a Mounjaro patient on basal insulin plus a sulfonylurea — even on the same tirzepatide dose. For the sibling Zepbound article, see Does Zepbound cause fatigue? SURMOUNT-1 rates and management evidence. For the parallel semaglutide article, see Does Wegovy cause fatigue? STEP-1 rates and management evidence.

Sulfonylurea and insulin co-prescription — practical caution

The Mounjaro label specifies that the concomitant insulin or sulfonylurea dose may need to be reduced when starting Mounjaro^[4]. In practice, prescribers handling T2D patients on Mounjaro almost universally do reduce or discontinue these agents. The American Diabetes Association Standards of Care recommend revisiting sulfonylurea prescriptions when adding a GLP-1 receptor agonist (or GLP-1/GIP dual agonist like tirzepatide) given the well-established hypoglycemia risk and the modest incremental glycemic benefit of continuing the sulfonylurea once a GLP-1-class agent is in place.

Patients should specifically ask their prescriber:

• If on a sulfonylurea (glipizide, glyburide, glimepiride): Should this be stopped or replaced before starting Mounjaro?
• If on basal insulin: What is the dose reduction plan when Mounjaro starts? (Typical starting reduction is 20%, with further reduction at each Mounjaro escalation step.)
• If on prandial (mealtime) insulin: Is this still needed once Mounjaro is on board? (Often the answer is no, because the GI-related reduction in food intake plus the glucose-lowering effect of tirzepatide make prandial insulin a frequent cause of postprandial hypoglycemia.)
• What is the hypoglycemia plan? Patients should have glucose tablets or another rapid-acting carbohydrate source readily available, especially during the first 12 weeks of Mounjaro.

For interactions with other medication classes, our GLP-1 drug interaction checker documents the specific dose-adjustment guidance for insulin, sulfonylureas, and the other glucose-lowering agents commonly co-prescribed in T2D.

Practical management — labs and lifestyle for Mounjaro fatigue

For all Mounjaro patients

First-line management of titration-phase fatigue on Mounjaro mirrors the Zepbound protocol with a T2D-specific overlay:

• Active hydration to 64–80 oz (2–2.5 L) per day, tracked. Plain water; oral rehydration salts during active GI symptoms (the WHO formulation or commercial equivalents like LMNT, Liquid IV, or Pedialyte) — plain-water rehydration in the setting of GI losses can produce dilutional hyponatremia, which is itself a fatigue trigger.
• Protein intake at 1.2–1.6 g per kg of lean body mass per day, distributed across 3–4 meals/snacks. Especially important for T2D patients, where protein stabilizes blood glucose more effectively than carbohydrate-dominant meals and reduces post-meal energy crashes.
• Morning rather than bedtime injection to shift the peak nausea window away from sleep hours.
• Slow titration if fatigue is dose-limiting. The FDA-approved 4-week escalation schedule is a minimum, not a requirement. Prescribers can hold patients at any dose for additional weeks. An extra 4 weeks at 5 mg or 7.5 mg is almost always the right move over pushing through active fatigue.

T2D-specific additions

• Capillary blood glucose check at the onset of any new fatigue episode — especially on combination therapy. Treat readings below 70 mg/dL with 15 g of rapid-acting carbohydrate.
• Continuous glucose monitor (CGM) trial if fatigue is recurrent and the prescriber suspects nocturnal hypoglycemia. Most major insurers now cover CGM for T2D patients on insulin.
• Diabetes regimen review at each Mounjaro escalation step. Background insulin or sulfonylurea dose reductions should be re-evaluated when moving from 5 → 10 mg and again from 10 → 15 mg, not just at Mounjaro initiation.
• HbA1c and fasting glucose recheck at week 12. A substantial drop in HbA1c with persistent fatigue often signals over-treatment from the rest of the regimen.

Lab workup if fatigue persists at a stable dose

Persistent fatigue beyond 4–8 weeks at a stable Mounjaro dose warrants a basic differential-diagnosis lab panel:

• Ferritin and complete blood count (CBC) — iron deficiency is the most-replicated non-thyroid driver of persistent adult fatigue and is common in T2D at baseline.
• Vitamin D 25-OH — deficiency is common in obesity and T2D from volumetric dilution into adipose tissue.
• Vitamin B12 (serum) — especially important if the patient is also on metformin, which independently reduces B12 absorption over months to years.
• TSH — both unrecognized hypothyroidism and Hashimoto’s are more prevalent in T2D.
• HbA1c and fasting glucose — rules out glycemic over-treatment patterns from combination therapy.

When to call your prescriber

Bottom line for the “Mounjaro fatigue” question

1. Fatigue is not on the Mounjaro Section 6.1 Table 1 adverse-reaction list. The label’s ≥5% AEs are GI events plus decreased appetite — fatigue, asthenia, lethargy, and malaise are absent. This contrasts with the Zepbound label, where SURMOUNT-1 fatigue runs 5–7% across doses. The most plausible reason is the smaller caloric deficit in the T2D pivotal pool (40-week, ~10% weight loss) versus SURMOUNT-1 (72-week, ~21% weight loss).
2. Hypoglycemia from combination therapy is the dominant T2D fatigue driver. Section 5.3 warns about it; Table 2 quantifies it (BG <54 mg/dL in 14–19% on Mounjaro + basal insulin, 10–14% on Mounjaro + sulfonylurea). On monotherapy, severe hypoglycemia is zero across all Mounjaro doses.
3. The fix is the diabetes regimen, not the Mounjaro. Reducing or stopping the concomitant insulin or sulfonylurea at Mounjaro initiation — and again at each escalation step — is the label-recommended response. Most prescribers reduce basal insulin by about 20% at Mounjaro start and consider stopping the sulfonylurea outright.
4. Caloric deficit and GI-induced dehydration drive the residual non-hypoglycemic fatigue. Same mechanism as Zepbound, smaller magnitude. Resolves within 2–4 weeks at a stable dose.
5. Management is conservative and stepwise. Protein at 1.2–1.6 g/kg lean body mass per day, hydration tracked to 64–80 oz, morning dosing, slower titration if dose-limiting, capillary glucose check at any new fatigue episode if on combination therapy.
6. Lab workup for persistent stable-dose fatigue. Ferritin, B12 (especially on metformin), vitamin D, TSH, HbA1c, and fasting glucose. The Mounjaro context shifts the threshold for ordering them sooner because the medication creates a plausible alternative explanation that can mask a real underlying deficiency for months.
7. Red flags are urgent. Hypoglycemia with symptoms, severe hypoglycemia requiring help, inability to keep fluids down for >24 hours, dark urine with reduced output, severe abdominal pain (pancreatitis), syncope, or sudden cognitive changes all warrant immediate evaluation.

For the broader Mounjaro clinical picture, the Mounjaro drug page consolidates FDA-approved indications, dose tiers, pricing, and provider availability. For the operational question of how to titrate through the first weeks without losing tolerability, see our GLP-1 side-effect Q&A hub. For the GI-cluster deep dive, see GLP-1 fatigue and hair loss duration evidence.